LECMC Biomarker Discovery Programme
|Status||Funding awarded/in set-up|
The Liverpool Experimental Cancer Medicine Centre (LECMC) seeks to support early phase trials and translational science in Liverpool, and through the ECMC network, more widely throughout the UK. One of the key strategic areas and objectives of the LECMC is to identify novel biomarkers of efficacy, resistance and drug safety in cancers including those of the pancreas, head and neck and breast. In order to achieve this, the scientists and clinicians within the LECMC need good quality prospective samples with linked data on treatments, side effects and outcomes. We intend to initiate a broad programme for biomarker discovery involving, initially, three research groups within the University of Liverpool with interests in key strategic areas of the LECMC. These are the Mersey Head and Neck Oncology Research Group, the Pancreatic Cancer Research Group and the Breast Cancer Research Group. We would like to collect appropriate samples from patients with cancer or pre-cancerous disease relevant to each of these groups for usage in research projects, specifically for the purpose of investigating biomarkers for cancers. In doing so we hope to enable research which would identify markers for surgical outcomes, responses to therapy and early diagnosis from a variety of sources; with a goal of leading to the development of personalised treatment regimes, stratifications of patients and development of preventative approaches to cancers.